Recruiting

Axonics SNM System

Sponsor:

Axonics, Inc.

Code:

NCT06789406

Conditions

Urinary Urge Incontinence (UUI)

Urinary Frequency (UF)

Overactive Bladder (OAB)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Axonics SNM System INS Model 5101 (R20)

Study Details

Brief summary:

Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the Axonics SNM System INS Model 5101.

Conditions

Urinary Urge Incontinence (UUI)

Urinary Frequency (UF)

Overactive Bladder (OAB)

Study ID

NCT06789406

Start date

Sep 18, 2025

Status verified date

Aug, 2026

Completion date

Oct, 2031

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. 18 years or older
2. Primary indication of OAB (urinary urgency incontinence (UUI) / urinary frequency (UF) who are not candidates for, or who have failed conservative treatment
3. Willing and capable to provide written consent and agrees to comply with specified evaluations at clinical centers for all follow-up assessments

Exclusion Criteria:

1. Any significant medical condition that is likely to interfere with procedures, device operation, or likely to confound evaluation of endpoints (i.e., neurological conditions such as multiple sclerosis)
2. Any psychiatric or personality disorder that is likely to interfere with procedures at the discretion of the participating physician; this may include poor understanding or compliance with requirements
3. Previously underwent an external sacral neuromodulation SNM trial and was deemed a non-responder or was previously implanted with a sacral neuromodulation device and did not get therapeutic benefit (a non-responder)
4. History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone
5. A female who is breastfeeding
6. A female with a positive urine pregnancy test

Study Design

Enrollment

55 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Overactive Bladder

Participants with the Axonics SNM System Model 5101 and followed up regarding their overactive bladder symptoms.

Interventions

Axonics SNM System INS Model 5101 (R20)

Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.

Primary outcome measure

  • Performance/Effectiveness - Improvement in Qualify of Life scoring (OAB) [ Time Frame: 3 months ]
  • Adverse event reporting (Safety) [ Time Frame: 3 months ]

Central Contacts and Locations

Locations

University of Chicago

Recruiting

Chicago, Illinois, United States, 60637

Principal Investigator:

Kimberly Kenton, MD

University of Missouri

Recruiting

Columbia, Missouri, United States, 65211

Principal Investigator:

Raymond Foster, MD

More Information

Sponsor

Axonics, Inc.

Last update posted

Aug 12, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Axonics, Inc. on 2026-08-12.